

Literatur

1. van Halm VP et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross sectional study. The CARRE investigation. *Ann Rheum Dis* 2008; Epub ahead of print.
2. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. *Am J Med* 2008; 121: S9–14.
3. Choi HK et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet* 2002; 359: 1173–1177.
4. Han C et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol* 2006; 33: 2167–2172.
5. Wallberg-Jonsson S et al. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. *J Rheumatol* 1997; 24: 445–451.
6. Solomon DH et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. *Arthritis Rheum* 2004; 50: 3444–3449.
7. Maradit-Kremers H et al. Cardiovascular death in rheumatoid arthritis: a population-based study. *Arthritis Rheum* 2005; 52: 722–732.
8. Chae CU et al. Blood pressure and inflammation in apparently healthy men. *Hypertension* 2001; 38: 399–403.
9. Bautista LE et al. Independent association between inflammatory markers (C-reactive protein, IL-6, and TNF-alpha) and essential hypertension. *J Hum Hypertens* 2005; 19: 149–154.
10. Vaziri ND and Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. *Nat Clin Pract Nephrol* 2006; 2: 582–593.
11. Li J et al. Inflammation in the genesis of hypertension and its complications—the role of angiotensin II. *Nephrol Dial Transplant* 2007; 22: 3107–3109.
12. Sesso HD et al. C-reactive protein and the risk of developing hypertension. *J Am Med Assoc* 2003; 290: 2945–2951.
13. Verma S et al. Endothelin antagonism and IL-6 inhibition attenuate the proatherogenic effects of C-reactive protein. *Circulation* 2002; 105: 1890–1896.
14. Wang CH et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. *Circulation* 2003; 107: 1783–1790.
15. Hoes JN et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2007; 66: 1560–1567.
16. Panoulas VF et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology* 2008; 47: 72–75.
17. Johnson AG, Nguyen TV and Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. *Ann Int Med* 1994; 121: 289–300.
18. Sowers JR et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. *Arch Intern Med* 2005; 165: 161–168.
19. Fogari R et al. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. *J Hypertens* 2002; 20: 1007–1014.
20. Wong DG et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. *Lancet* 1986; 1: 997–1001.
21. Cífková R and Hallen H. Cyclosporin-induced hypertension. *J Hypertens* 2001; 19: 2283–2285.
22. Cohen S et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. *Arthritis Rheum* 2001; 44: 1984–1992.
23. Listing J et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? *Arthritis Rheum* 2008; 58: 667–677.
24. <http://www.leitlinien.net/046-001.pdf>
25. Dandona et al. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. *J Hum Hypertens* 2007; 21: 20–27.